Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Opdivo (nivolumab)
i
Other names:
ONO-4538, BMS-936558, MDX-1106, NSC 748726, ono-0123, GTPL7335, GTPL 7335, BMS936558, BMS 936558, GTPL-7335, MDX1106, MDX 1106, ONO4538, ONO 4538
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(607)
News
Trials
Company:
BMS, Ono Pharma
Drug class:
PD1 inhibitor
Related drugs:
‹
pembrolizumab (726)
sintilimab (115)
toripalimab-tpzi (88)
camrelizumab (85)
tislelizumab-jsgr (84)
dostarlimab-gxly (42)
cemiplimab-rwlc (29)
PDR001 (22)
zimberelimab (20)
ABBV-181 (13)
pucotenlimab (12)
cadonilimab (10)
AGEN2034 (9)
penpulimab (7)
serplulimab (6)
retifanlimab-dlwr (6)
PF-06801591 (6)
JNJ-63723283 (5)
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
geptanolimab (3)
ivonescimab (3)
PSB205 (3)
MEDI0680 (2)
QL1604 (2)
CS1003 (2)
BMS-202 (1)
BRL-201 (1)
IMU-201 (1)
Opal (1)
BI 754091 (1)
JTX-4014 (1)
AZD2936 (1)
MEDI5752 (1)
XmAb717 (1)
609A (0)
(0)
AI-061 (0)
AMP-224 (0)
ASKG915 (0)
AUNP-12 (0)
AWT020 (0)
(0)
BAT1306 (0)
BAT1308 (0)
BGB-108 (0)
BZD1901 (0)
BiCKI IL-7 (0)
CB213 (0)
CD200AR-L (0)
CDX-585 (0)
CMAB 819 (nivolumab biosimilar) (0)
EBV-specific anti-PD1 TCR-T cells (0)
EMB-02 (0)
enlonstobart (0)
prolgolimab (0)
GNR-051 (0)
HX-009 (0)
IAP0971 (0)
INCA32459 (0)
INCA33890 (0)
JS201 (0)
KJ-101 (0)
LB1410 (0)
MASCT-I (0)
MB12 (0)
MVR-C5252 (0)
MVR-T7011 (0)
NY-ESO-1 TCR-T cell therapy (0)
prolgolimab/nurulimab (0)
ONCR-177 (0)
OSE-279 (0)
PD-1-KO-T cell injection (0)
PF-07209960 (0)
PH-3861 (0)
PH-762 ACT (0)
PRGN-3007 (0)
(0)
RB-340 (0)
SAR445877 (0)
SL-279252 (0)
SSGJ-705 (0)
SYN125 (0)
Sym021 (0)
T3011 (0)
TQB2868 (0)
TY 101 (0)
Undisclosed PD-1 inhibitor (0)
Undisclosed anti PD-1 mAb (0)
WTX212 (0)
XKDCT086 (0)
ZG005 (0)
YBL-006 (0)
anti-PD-1 antibody (0)
SI-B003 (0)
RG6279 (0)
MK-4280A (0)
IBI315 (0)
SCT-I10A (0)
XmAb23104 (0)
AMG 256 (0)
LZM009 (0)
RG7769 (0)
MGD019 (0)
BMS-986298 (0)
MK-3475 SC (0)
CT-011 (0)
LVGN3616 (0)
MK-1308A (0)
IBI318 (0)
F520 (0)
AZD7789 (0)
RG6139 (0)
JS001sc (0)
MK-7684A (0)
AMG 404 (0)
pembrolizumab (726)
sintilimab (115)
toripalimab-tpzi (88)
camrelizumab (85)
tislelizumab-jsgr (84)
dostarlimab-gxly (42)
cemiplimab-rwlc (29)
PDR001 (22)
zimberelimab (20)
ABBV-181 (13)
pucotenlimab (12)
cadonilimab (10)
AGEN2034 (9)
penpulimab (7)
serplulimab (6)
retifanlimab-dlwr (6)
PF-06801591 (6)
JNJ-63723283 (5)
MGD013 (5)
nivolumab/relatlimab-rmbw (4)
geptanolimab (3)
ivonescimab (3)
PSB205 (3)
MEDI0680 (2)
QL1604 (2)
CS1003 (2)
BMS-202 (1)
BRL-201 (1)
IMU-201 (1)
Opal (1)
BI 754091 (1)
JTX-4014 (1)
AZD2936 (1)
MEDI5752 (1)
XmAb717 (1)
609A (0)
(0)
AI-061 (0)
AMP-224 (0)
ASKG915 (0)
AUNP-12 (0)
AWT020 (0)
(0)
BAT1306 (0)
BAT1308 (0)
BGB-108 (0)
BZD1901 (0)
BiCKI IL-7 (0)
CB213 (0)
CD200AR-L (0)
CDX-585 (0)
CMAB 819 (nivolumab biosimilar) (0)
EBV-specific anti-PD1 TCR-T cells (0)
EMB-02 (0)
enlonstobart (0)
prolgolimab (0)
GNR-051 (0)
HX-009 (0)
IAP0971 (0)
INCA32459 (0)
INCA33890 (0)
JS201 (0)
KJ-101 (0)
LB1410 (0)
MASCT-I (0)
MB12 (0)
MVR-C5252 (0)
MVR-T7011 (0)
NY-ESO-1 TCR-T cell therapy (0)
prolgolimab/nurulimab (0)
ONCR-177 (0)
OSE-279 (0)
PD-1-KO-T cell injection (0)
PF-07209960 (0)
PH-3861 (0)
PH-762 ACT (0)
PRGN-3007 (0)
(0)
RB-340 (0)
SAR445877 (0)
SL-279252 (0)
SSGJ-705 (0)
SYN125 (0)
Sym021 (0)
T3011 (0)
TQB2868 (0)
TY 101 (0)
Undisclosed PD-1 inhibitor (0)
Undisclosed anti PD-1 mAb (0)
WTX212 (0)
XKDCT086 (0)
ZG005 (0)
YBL-006 (0)
anti-PD-1 antibody (0)
SI-B003 (0)
RG6279 (0)
MK-4280A (0)
IBI315 (0)
SCT-I10A (0)
XmAb23104 (0)
AMG 256 (0)
LZM009 (0)
RG7769 (0)
MGD019 (0)
BMS-986298 (0)
MK-3475 SC (0)
CT-011 (0)
LVGN3616 (0)
MK-1308A (0)
IBI318 (0)
F520 (0)
AZD7789 (0)
RG6139 (0)
JS001sc (0)
MK-7684A (0)
AMG 404 (0)
›
Associations
(607)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Esophageal Adenocarcinoma
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Gastric Cancer
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Squamous Cell Carcinoma of Head and Neck
No biomarker
Squamous Cell Carcinoma of Head and Neck
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastric Cancer
HER-2 negative + PD-L1 expression
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Esophageal Adenocarcinoma
HER-2 negative + PD-L1 expression
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
LDH elevation
Melanoma
LDH elevation
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login